Acalabrutinib-Related Cardiac Toxicities in Patients with Chronic Lymphocytic Leukemia: A Meta-Analysis of Randomized Controlled Trials

Acalabrutinib, a second-generation and more selective Bruton's tyrosine kinase inhibitor, was developed to potentiate efficacy while minimizing ibrutinib-associated side effects. We undertook a systematic review and meta-analysis of randomized clinical trials to determine the risks of acalabrut...

Descripción completa

Detalles Bibliográficos
Autores principales: Htut, Thura Win, Han, Myat Min, Thein, Kyaw Zin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Innovative Healthcare Institute 2021
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9153250/
https://www.ncbi.nlm.nih.gov/pubmed/35664088
http://dx.doi.org/10.36401/JIPO-21-12

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9153250/
https://www.ncbi.nlm.nih.gov/pubmed/35664088
http://dx.doi.org/10.36401/JIPO-21-12

Ejemplares similares